App-Quantinova.ai

Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC).

Maria E. Cabanillas - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Thyroid Cancer

Cabozantinib

Activity of cabozantinib (XL184) in metastatic NSCLC: Results from a phase II randomized discontinuation trial (RDT).

Beth A. Hellerstedt - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cabozantinib

Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT).

Michael S. Gordon - American Society of Clinical Oncology (ASCO) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Cabozantinib

A phase I study of the multikinase inhibitor cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).

Fatima H. Karzai - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC).

Andrea Borghese Apolo - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced Urothelial Carcinoma

Cabozantinib

Assessment of bone metastases in patients (pts) with urothelial carcinoma using 18F-sodium fluoride PET/CT (18F-NaF) versus 18F-fluorodeoxyglucose PET/CT (18F-FDG).

Benjamin Adam Weinberg - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Cabozantinib

Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib.

Paul G. Corn - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).

Andrea Borghese Apolo - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2013

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Bladder Cancer

Cabozantinib

Activity of cabozantinib (XL184) in hepatocellular carcinoma patients (pts): Results from a phase II randomized discontinuation trial (RDT).

Allen Lee Cohn - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Cabozantinib

Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).

Toni K. Choueiri - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2012

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Cabozantinib

RET M918T-exon 16 mutation in subjects with sporadic medullary thyroid cancer (sMTC)

Miljenko Solter - European Congress of Endocrinology (ECE) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Thyroid Cancer

Cabozantinib

Identification of existing targeted agents that inhibit NTRK and ROS1 in lung cancer

Curtis Chong - American Association for Cancer Research (AACR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Cabozantinib

The identification and structure-guided optimisation of potent and selective inhibitors of oncogenes in medullary thyroid carcinoma and lung adenocarcinoma

Roger J. Butlin - American Association for Cancer Research (AACR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Medullary thyroid carcinoma

Cabozantinib

Effects of combination treatment with cabozantinib and bortezomib in the 5TGM1 murine multiple myeloma model

Mari I. Suominen - American Association for Cancer Research (AACR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

Cabozantinib eradicates de novo castrate-resistant PTEN/p53 deficient murine prostate cancer via activation of neutrophil-mediated anti-tumor innate immunity

Akash Patnaik - American Association for Cancer Research (AACR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Unspecified Cancer

Cabozantinib

Tumor response to cabozantinib in the TH-MYCN GEM model of neuroblastoma

Gilberto S. Almeida - American Association for Cancer Research (AACR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Neuroblastoma

Cabozantinib

Drosophila models of Ret fusions in papillary thyroid carcinoma

Sarah Levinson - American Association for Cancer Research (AACR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Papillary carcinoma

Cabozantinib

Cabozantinib, a multi-target receptor tyrosine kinase inhibitor, decreases tumor growth and angiogenesis in a patient-derived dedifferentiated liposarcoma xenograft

Haifu Li - American Association for Cancer Research (AACR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liposarcomas

Cabozantinib

Multi-targeted tyrosine kinase inhibitor Cabozantinib as a therapeutic agent in MET-overexpressing gastric cancer

Audrey H. Choi - American Association for Cancer Research (AACR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Cabozantinib

Effect of target therapies in liver cancer PDX tumor models: Response, resistance and predictive biomarkers

Tengfei Yu - American Association for Cancer Research (AACR) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

Cabozantinib

Filters

366 Abstracts